Policy strategist Kristi Martin discusses how the Orphan Drug Act reshapes rare disease treatment and drug-pricing challenges ...

The Orphan Drug Act has boosted treatments, but Kristi Martin, MPA, MA, urges modernizing incentives and pricing to sustain future innovation Since its inception in 1983, the Orphan Drug Act has been ...

Republican Sen. Chuck Grassley, chairman of the Senate Judiciary Committee, has opened an inquiry into potential abuses of the Orphan Drug Act that may have contributed to high prices on commonly used ...

Sen. Chuck Grassley, R-Iowa, launched an inquiry into whether a loophole in the Orphan Drug Act could have contributed to high drug costs for many common medications, reports Kaiser Health News. Here ...

GAO finds flaws in FDA’s orphan drug program: 6 things to know The FDA failed to consistently record and evaluate necessary information to ensure drugs given the prized rare-disease designation met ...

"The Orphan Drug Act has been a great success because many people with diseases that affect very few people now have drugs available to them," Waxman said. "But it's been in some ways turned on its ...

The Orphan Drug Act of 1983 recognized the reality of the marketplace as an important factor influencing the development of new medications. Since 1983, hundreds of orphan compounds have been "adopted ...

SHELTON, CONNECTICUT / ACCESS Newswire / February 10, 2026 / NanoViricides, Inc., a publicly traded company (NYSE ...